Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Franco

Orthopaedic Surgery Elkhorn, NE Medical Doctor

NPI 1659391050 CMS profile 166341

222 N 192Nd St, Elkhorn, NE 68022

Open in the dashboard

General payments

$3,979

28 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Franco of Elkhorn, NE is reported in the CMS Open Payments database as having received $3,979 across 28 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $129 2
2024 General $198 2
2021 General $334 4
2019 General $3,318 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Franco
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Mark Franco were reported at $129. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Mark Franco Orthopaedic Surgery median Middle half National median
2019 $3,318 $644 $140–$2,844 $163
2020 $0 $312 $75–$1,860 $114
2021 $334 $520 $117–$2,495 $132
2022 $0 $598 $128–$2,731 $149
2023 $0 $461 $128–$2,264 $160
2024 $198 $497 $134–$2,475 $164
2025 $129 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $2,197 16 payments
  2. Smith+Nephew, Inc. $1,428 6 payments
  3. Conetic Solutions, Inc. $303 3 payments
  4. Stryker Corporation $25 1 payment
  5. DePuy Synthes Sales Inc. $13 1 payment
  6. AbbVie, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,437 5 payments
  2. Food and Beverage $1,255 21 payments
  3. Education $287 2 payments
Products named General payments · program years 2019–2025
  1. Echo $1,383 3 payments
  2. POLARCUP $815 3 payments
  3. Journey II BCS $756 2 payments
  4. VERILAST Hips $714 2 payments
  5. Journey II XR $346 1 payment
  6. VISIONAIRE Cutting Guides $346 1 payment
  7. Persona Knees $336 4 payments
  8. Navio Surgical System $326 3 payments
  9. Persona Knees $287 2 payments
  10. Legion Revision $267 2 payments
  11. Other $661 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

92

Median for Orthopedic Surgery: 203

Drug cost

$559

Median for Orthopedic Surgery: $1,433

Branded share of claims

66.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 35 $315
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $197
Tramadol Hcl Generic 15 $33
Amoxicillin Generic 16 $14

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$98,655

Of which drugs: $3,123

Medicare patients

196

Average age 77

Services billed

1,370

127 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 30%
Chronic kidney disease 29%
Depression 29%
Diabetes 27%
Osteoporosis 25%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 51 670 $456

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record